Tratamiento hormonal vs quimioterapia en recidiva de cáncer de ovario en mujeres de 50-75 años atendidas en el hospital Teodoro Maldonado Carbo en el año 2019.

Abstract

Introduction: Currently in Ecuador hormone therapy is used as a post-surgical treatment in ovarian cancer in 40% of patients. Chemotherapy continues to be the first-choice post-surgical treatment in Ecuador applied to 60% of women. Several studies show that the use of chemotherapy increases survival up to 12 months. Therefore, the objective of this study is to demonstrate the efficacy of chemotherapy over hormonal therapy. Materials and methods: A descriptive, observational cross-sectional study was carried out reviewing the medical records of patients treated at the Teodoro Maldonado Carbo Hospital in 2019. Results: The Kaplan-Meier survival test obtained: chemotherapy (median survival : 11; CI: 9.89-12.01) and those who received tamoxifen (median survival: 8; CI: 6.64-9.35), p-value 0.001 using the Long Rank test. Tamoxifen causes adverse effects in more patients (n = 67, 87.01%), than chemotherapy (n = 123, 74.54%). Alopecia with 33/77 cases (37.66%) was more frequent with tamoxifen and with chemotherapy it was anemia with 65/165 (38.18%). The risk of adverse effects was: tamoxifen (OR: 28.95; CI: 13.75-60.98), chemotherapy (OR: 5.7; CI: 3.11-10.42). Conclusions: Chemotherapy is more effective than hormonal treatment in the postoperative stage of ovarian cancer, as it achieves a longer time without recurrences, which is why the hypothesis of this study is accepted. Tamoxifen causes adverse effects in more patients than chemotherapy. And the risk of these adverse effects is lower in the chemotherapy group.